SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)


NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Levi & Korsinsky informs investors that it has initiated an investigation into Alnylam Pharmaceuticals, Inc. (“Alnylam”) (NASDAQ: ALNY) regarding possible violations of the federal securities laws.

On September 13, 2023, Alnylam announced that the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the United States Food and Drug Administration (FDA) approved Alnylam's application to expand the approval of Onpattro to patients with ATTR cardiomyopathy (CM). Analysts commenting on the approval noted that the FDA was not overly positive and “emphasized the small effects of the treatment and was apparently negative on clinical significance.” Following this news, Alnylam's stock price fell $18.59 per share, or approximately 4%, to close at $193.06 per share. Additionally, on October 9, 2023, Alnylam issued a press release announcing that the FDA has issued a Complete Response Letter (CRL) regarding the company's “Supplemental New Drug Application (sNDA)” for patisiran for the treatment of transthyretin (ATTR) amyloidosis cardiomyopathy.” Alnylam announced that the CRL stated that “the clinical significance of the therapeutic effects of patisiran for ATTR amyloidosis cardiomyopathy has not been established and, therefore, the sNDA for patisiran could not be approved in its current form.” As a result, the Company announced that it would no longer pursue the extension of the indication for patisiran in the United States. Following this news, the course of Alnylam's stock fell $2.53 per share, or about 2%, to close at $165.29 per share. For additional information, visit:

https://zlk.com/pslra-1/alnylam-lawsuit-submission-form?prid=66088&wire=1

or contact Joseph E. Levi, Esq. either by email at [email protected] or by telephone at (212) 363-7500.

WHY LÉVI & KORSINSKI: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally recognized securities litigation firm that has obtained hundreds of millions of dollars for injured shareholders and amassed a track record of victories in high-stakes cases. The firm has extensive expertise in representing investors in complex securities litigation and a team of more than 70 employees to serve our clients. For seven consecutive years, Levi & Korsinsky has been ranked in the ISS Securities Class Action Services Top 50 Report as one of the top securities litigation firms in the United States. Lawyer advertising. Previous results do not guarantee similar results.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, New York 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

View original Press release on accesswire.com



Source link

Scroll to Top